Donna Berry on the Implications of Oral Oncolytics

Article

Donna Berry from the Phyllis F. Cantor Center at the Dana-Farber Cancer Institute on the Implications of Oral Oncolytics

Donna Berry, PhD, RN, AOCN®, FAAN, from the Phyllis F. Cantor Center at the Dana-Farber Cancer Institute on the implications of oral oncolytics as observed in her research on patient adherence to oral oncolytic therapy, symptom management, patient quality of life, and patient decision making in cancer treatment.

Recent Videos
Anne M. Reb, PhD, NP, discussing a nurse-led intervention for fear of cancer recurrence.
Ann H. Partridge, MD, MPH, in an interview with Oncology Nursing News at 2024 ESMO Congress.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.